Netradyne | $90,000,000 | (Jan 17, 2025)
Truewind | $13,000,000 | (Jan 17, 2025)
Peregrine Health | $5,000,000 | (Jan 17, 2025)
Certified by Founder
Lodge
Indapta Therapeutics
start up
United States
- Seattle & Houston
- 18/12/2024
- Unknown
- $22,500,000
Indapta's allogeneic g-NK cells have highly potent ADCC activity, making them the ideal therapy to combine with IgG1 monoclonal antibodies, ADCs, or innate immune cell engager molecules.
- Industry Biotechnology
- Website https://indapta.com/
- LinkedIn https://www.linkedin.com/company/indapta-therapuetics/
Guidesly | $9,500,000 | (Jan 17, 2025)
Alium | $7,000,000 | (Jan 17, 2025)
Pipe17 | $15,500,000 | (Jan 17, 2025)
Coram AI | $13,800,000 | (Jan 17, 2025)
Quantifind | $22,000,000 | (Jan 17, 2025)
Hyperline | $10,000,000 | (Jan 17, 2025)
Origen | $13,000,000 | (Jan 17, 2025)
Komainu | $75,000,000 | (Jan 17, 2025)
Hinge Bio | $30,000,000 | (Jan 16, 2025)